Japanese encephalitis vaccine

Source: Wikipedia, the free encyclopedia.

Japanese encephalitis vaccine
Japanese encephalitis vaccine Encevac
Vaccine description
TargetJapanese encephalitis
Vaccine typeInactivated or attenuated
Clinical data
Trade namesIxiaro, Imojev
AHFS/Drugs.comMonograph
MedlinePlusa607019
License data
Pregnancy
category
ATC code
Legal status
Legal status
Identifiers
CAS Number
ChemSpider
  • none
 ☒NcheckY (what is this?)  (verify)

Japanese encephalitis vaccine is a

just under the skin.[2]

It is recommended as part of

pregnant an inactivated vaccine should be used.[2] Immunization of travellers who plan to spend time outdoors in areas where the disease is common is recommended.[2]

The vaccines are relatively safe.[2] Pain and redness may occur at the site of injection.[2] As of 2015, 15 different vaccines are available:[2] some are based on recombinant DNA techniques, others weakened virus, and others inactivated virus.[2]

The Japanese encephalitis vaccines first became available in the 1930s.[3] It is on the World Health Organization's List of Essential Medicines.[4][5]

Efficacy

Randomized control trials on JE-VAX have shown that a two-dose schedule provides protection for one year.[6]

History

Japanese encephalitis vaccines first became available in the 1930s.

People's Republic of China from 1968 until 2005.[7]

Three second-generation vaccines have entered markets since then: SA14-14-2, IC51 and ChimeriVax-JE. The live-attenuated SA14-14-2 strain was introduced in China in 1988. It is much cheaper than alternative vaccines, and is administered to 20 million Chinese children each year.[6]

A purified, formalin-inactivated, wholevirus vaccine known as IC51 (marketed in Australia and New Zealand as JESPECT and elsewhere as IXIARO) was licensed for use in the United States, Australia, and Europe during the spring of 2009. It is based on a SA14-14-2 strain and cultivated in Vero cells.[7] In September 2012, the Indian firm Biological E. Limited launched an inactivated cell culture derived vaccine based on SA 14-14-2 strain which was developed in a technology transfer agreement with Intercell and is a thiomersal-free vaccine.[8][9]

Another vaccine, a live-attenuated recombinant chimeric virus vaccine developed using the Yellow fever virus[10] known as ChimeriVax-JE (marketed as IMOJEV) was licensed for use in Australia in August 2010[11] and in Thailand in December 2012.[12]

References

  1. ^ a b Use During Pregnancy and Breastfeeding
  2. ^
    PMID 25726573.
    "Summary of the WHO Position Paper on Vaccines against Japanese encephalitis (JE)" (PDF). Archived from the original
    (PDF) on 6 June 2015.
  3. ^
    S2CID 7170010
    . Furthermore, vaccines against JEV have been available since the 1930s.
  4. hdl:10665/325771
    . WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  5. hdl:10665/345533
    . WHO/MHP/HPS/EML/2021.02.
  6. ^
    PMID 17636750
    .
  7. ^
    PMID 20218889
    .
  8. ^ "Jeev an inactivated Japanese Encephalitis vaccine launched in Hyderabad". pharmabiz.com. 15 September 2012. Archived from the original on 23 October 2012. Retrieved 11 January 2013.
  9. ^ Bryant A (17 September 2012). "Intercell's Jeev vaccine debuts in India". Archived from the original on 19 January 2013. Retrieved 11 January 2013.
  10. S2CID 35567599
    .
  11. S2CID 31362697
    .
  12. ^ "Drug joint venture plans new vaccine". Bangkok Post. 2 November 2013. Retrieved 18 December 2013.

External links

Retrieved from "https://en.wikipedia.org/w/index.php?title=Japanese_encephalitis_vaccine&oldid=1174764385"